This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Informatica Helps ICON Improve Clinical Trials Management System

REDWOOD CITY, Calif.,, March 6, 2014 (GLOBE NEWSWIRE) -- Informatica Corporation (Nasdaq:INFA), the world's number one independent provider of data integration software, today announced that ICON plc is improving the company's clinical trials and development process with Informatica. By standardizing on a best-in-class, multidomain Informatica MDM solution, this global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries is creating a consolidated and reliable view of business-critical data -- such as investigators and sites -- and the relationships between the data. This strategy is unleashing the potential of ICON's data: unlocking faster, better-informed decisions, including clinical trial planning, trial execution services and improved reporting. 

Commenting on the Informatica MDM deployment, Andrew Thompson, vice president of technology, ICON, said, "Our business is all about data. Informatica unlocks the potential of ICON's data, delivering 360-degree insights into, study and site related program activities. This enables the company to continuously monitor the clinical trials process, optimize operations based on real-time alerts and data insights and mitigate risk. The ultimate outcome is increased productivity."

ICON is one of a small group of organizations with the scale, range of services and expertise to conduct clinical trials globally. Some trials have several hundred patients, some have several thousand and the trials can run for many years.

Informatica MDM helps ICON realize the potential of data with a consolidated view of investigators and sites across the end-to-end clinical trials management spectrum. Now with a single view of an investigator, ICON has a much improved performance analysis capability.   Improvement in future study initiation has followed so that ICON delivers greater excellence in execution.

At the same time, the multidomain solution enables the company to track site enrollment and performance more effectively and highlight non-performing sites earlier. This helps ensure only high performance sites participate in clinical trials. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs